{"nctId":"NCT01734785","briefTitle":"Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes","startDateStruct":{"date":"2013-02-08","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":607,"armGroups":[{"label":"Linagliptin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Linagliptin","Drug: Empagliflozin placebo + Linagliptin placebo"]},{"label":"Empagliflozin + Linagliptin low dose","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin + Linagliptin"]},{"label":"Empagliflozin + Linagliptin high dose","type":"EXPERIMENTAL","interventionNames":["Drug: Empagliflozin + Linagliptin"]}],"interventions":[{"name":"Linagliptin","otherNames":[]},{"name":"Empagliflozin + Linagliptin","otherNames":[]},{"name":"Empagliflozin + Linagliptin","otherNames":[]},{"name":"Empagliflozin + Linagliptin","otherNames":[]},{"name":"Empagliflozin placebo + Linagliptin placebo","otherNames":[]},{"name":"Empagliflozin + Linagliptin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of type 2 diabetes mellitus.\n2. Male and female patients on diet and exercise regimen, pre-treated with immediate release metformin for at least 12 weeks, and patients should be on a dose higher or equal to 1500 mg/day of metformin, or maximum tolerated dose, or maximum dose as per local label.\n3. HbA1c higher or equal to 8.0% and lower or equal to 10.5% at screening visit.\n4. Age 18 years or more at screening.\n5. Body Mass Index lower or equal to 45 kg/m2 at screening visit.\n6. Signed and dated written informed consent.\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycemia with glucose level above 270 mg/dl (above 15 mmol/dl) after an overnight fast.\n2. Use of any other antidiabetic drug (except metformin background therapy).\n3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent.\n4. Indication of liver disease.\n5. Impaired renal function.\n6. Gastrointestinal surgery.\n7. Treatment with anti-obesity drugs within 3 months prior to screening, or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight.\n8. Current treatment with systemic steroids at time of informed consent or uncontrolled endocrine disorder except type 2 diabetes mellitus.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment","description":"Change from baseline in Glycated haemoglobin (HbA1c) \\[%\\] after 24 weeks of treatment with double-blind trial medication. Baseline was defined as the last observation before the first intake of any double-blind randomised trial medication. The term 'baseline' was not used to refer to measurements before the administration of open-label medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.56","spread":"0.08"},{"groupId":"OG001","value":"-0.65","spread":"0.08"},{"groupId":"OG002","value":"0.14","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline After 24 Weeks of Double-blind Treatment.","description":"Change from baseline FPG (mmol/L) after 24 weeks of treatment with double-blind trial medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.75","spread":"0.18"},{"groupId":"OG001","value":"-1.46","spread":"0.18"},{"groupId":"OG002","value":"0.34","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Body Weight Change From Baseline After 24 Weeks of Double-blind Treatment","description":"Change from baseline Body weight after 24 weeks of treatment with double-blind trial medication.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.52","spread":"0.25"},{"groupId":"OG001","value":"-3.06","spread":"0.25"},{"groupId":"OG002","value":"-0.30","spread":"0.26"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":110},"commonTop":["Urinary tract infection","Nasopharyngitis","Headache","Lipase increased","Hyperglycaemia"]}}}